Curis, Inc. (CRIS)
After hours:
| Previous Close | 10.66 |
| Open | 10.58 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 10.58 - 10.84 |
| 52 Week Range | 0.38 - 17.49 |
| Volume | |
| Avg. Volume | 27,393 |
| Market Cap | 63.774M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Curis Announces Additional Data from TakeAim Leukemia Study
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences.
- PR Newswire
Curis to Present Updated Data from the TakeAim Leukemia Study
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET. Management will host a conference call on the same day at 4:30 p.m. ET.
- PR Newswire
Curis Provides First Quarter 2024 Business Update
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2024.
